home / stock / scyx / scyx news

SCYX News and Press, SCYNEXIS Inc. From 09/29/21

Stock Information
Company Name: SCYNEXIS Inc.
Stock Symbol: SCYX
Market: NASDAQ
Website: scynexis.com
Menu
SCYX SCYX Quote SCYX Short SCYX News SCYX Articles SCYX Message Board
Get SCYX Alerts

News, Short Squeeze, Breakout and More Instantly...
SCYX - SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp

JERSEY CITY, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced an oral presentation of analyses of interim data from its on...
SCYX - SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections

JERSEY CITY, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced one oral and two poster presentations of interim data f...

SCYX - SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years

First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including cloud-based pharmacy New treatment is fungicidal against Candida species, disrupting the fungal cell wall and killing the fungi causing the infection...

SCYX - SCYNEXIS Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)

JERSEY CITY, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Hansoh Pharmaceutical Group Company Limited (Hansoh Pha...
SCYX - SCYNEXIS to Participate in Upcoming Investor Conferences

JERSEY CITY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virt...

SCYX - 2 Small-Cap Healthcare Stocks Wall Street Predicts Will Rally by More Than 200%

The healthcare industry is expected to witness increasing demand amid an aging population. As such, Wall Street analysts expect small-cap healthcare stocks BeyondSpring (BYSI) and SCYNEXIS (SCYX) to gain significantly in the coming months. So, it could be wise to add these two stocks to one&#...

SCYX - SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update

BREXAFEMME ® (ibrexafungerp tablets), the first novel antifungal class drug approved by the U.S. Food and Drug Administration (FDA) in more than 20 years, qualifies for 10 years of regulatory exclusivity and has 14 years of U.S. patent protection U.S. commercial...
SCYX - Acurx Pharmaceuticals Joins the Antimicrobials Working Group

Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire WASHINGTON , Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of c...

SCYX - SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting

The pooled data from two Phase 3 studies (VANISH-303 and VANISH-306) of one-day oral ibrexafungerp reflect a population that overwhelmingly had severe yeast infections, a condition typically treated with multiple doses of oral fluconazole Ibrexafungerp demonstrated consistent ...

SCYX - Scynexis: Leading The Yeast Infection Treatment Industry

SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections. BREXAFEMME is the first approved drug in the non-azole class for VVC and also the first approved drug in a novel antifungal clas...
Previous 10 Next 10